Related Experiment Video

Updated: Sep 23, 2025

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K

Peptide PDHPS1 Inhibits Ovarian Cancer Growth through Disrupting YAP Signaling

Xinxing Pan1, Zhe Geng1, Jingyun Li2

  • 1Department of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu, China.

Molecular Cancer Therapeutics
|May 11, 2022
PubMed

Insights

The endogenous peptide PDHPS1 inhibits ovarian cancer growth by targeting the YAP signaling pathway. This novel antitumor peptide shows no observable side effects on normal tissues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Peptide Therapeutics

Background:

  • Ovarian cancer metastasis and drug resistance pose significant threats to patients.
  • Endogenous peptides are emerging as promising therapeutic agents in oncology.
  • Few anti-ovarian cancer peptides have been identified, highlighting a need for new therapeutic strategies.

Purpose of the Study:

  • To investigate the biological roles and mechanism of the endogenous peptide PDHPS1 in ovarian cancer development.
  • To evaluate the therapeutic potential of PDHPS1 against ovarian cancer.

Main Methods:

  • In vitro and in vivo studies to assess PDHPS1's effect on ovarian cancer cell proliferation and tumor growth.
  • Peptide pull-down assays, mass spectrometry, Western blot, and qRT-PCR to identify PDHPS1's molecular targets.
  • Flow cytometry, cell membrane permeability tests, and IHC staining to evaluate PDHPS1's safety profile.

Main Results:

  • PDHPS1 significantly reduced ovarian cancer cell proliferation in vitro and inhibited tumor growth in vivo.
  • PDHPS1 binds to protein phosphatase 2 phosphatase activator (PTPA), increasing phosphorylated YAP and suppressing its downstream target genes.
  • PDHPS1 demonstrated no observable side effects on normal ovarian epithelium and hepatorenal function.

Conclusions:

  • The endogenous peptide PDHPS1 acts as an antitumor agent by inhibiting the YAP signaling pathway through interaction with PTPA in ovarian cancer.
  • PDHPS1 represents a potential therapeutic candidate for ovarian cancer treatment.
  • Modifications to enhance membrane penetration could further improve PDHPS1's therapeutic efficacy.

More Related Videos

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

11.1K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K